EPS growth is an important number as it indicates the future prospects of Aileron Therapeutics. It is usually expressed as a percentage and is then referred to as the EPS growth rate, which at this time is unavialble, but historically the EPS change was -16.28% over the last twelve months. The long-term trend in EPS shows how well the management of Aileron Therapeutics is adding value for shareholders.

Aileron Therapeutics is part of the biotechnology industry and is part of the healthcare sector. The company CEO is Manuel C. Aivado. Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company that is focused on developing and commercializing a novel class of therapeutics called stapled peptides. The company’s lead candidate is ALRN-6924.

Previous Intraday Performance:

The ALRN shares had a previous change of -0.60% which opened at 1.70 and closed at 1.67. It moved to an intraday high of 1.78 and a low of 1.62.

SeekingAlpha:  Healthcare and Tech tops midday movers

Historical Performance:

Over the last five trading days, ALRN shares returned -3.47% and in the past 30 trading days it returned 125.68%. Over three months, it changed -8.24%. In one year it has changed -78.06% and within that year its 52-week high was 9.50 and its 52-week low was 0.52. ALRN stock is 221.15% above its 52 Week Low.

Our calculations result in a 200 day moving average of 3.16 and a 50 day moving average of 1.37. Right now, ALRN stock is trading -47.10% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  Healthcare and Tech tops midday movers


The company has a market cap of $24.6m with 14.7m shares outstanding and a float of 14.1m shares. Trading volume was 136,606 shares and has experienced an average volume of 258,909 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for Aileron Therapeutics was -11.73 which ended on 31st of December 2017. Based on 3 analyst estimates, the consensus EPS for the next quarter is -0.50.

Below was the last reported quarterly earnings per share:
09-30-2018:  -0.50
06-30-2018:  -0.56
03-31-2018:  -0.52
12-31-2017:  -0.47

Base on our calculations, the intrinsic value per share is 120.62, which means it might be undervalued and has a margin of safety of 98.62%

Indicators Also to Watch:

Based on the latest filings, there is 22.30% of institutional ownership.

I calculated the beta to be -2.13

PR Newswire:  Agenus to Launch the First Asset-Backed Digital Security Offering in Healthcare

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -78.95%, return on assets is -64.99% and price-to-book is 0.95.

Company Score Card:

Results are out of six:
 2  : Growth Expectations Result
 4  : Financial Safety Result
 0  : Past Performance Result
 3  : Valuation Result
 0  : Dividend Safety Result
 2  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here